These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 36005269)

  • 1. Oral Fosfomycin Formulation in Bacterial Prostatitis: New Role for an Old Molecule-Brief Literature Review and Clinical Considerations.
    Marino A; Stracquadanio S; Bellanca CM; Augello E; Ceccarelli M; Cantarella G; Bernardini R; Nunnari G; Cacopardo B
    Infect Dis Rep; 2022 Aug; 14(4):621-634. PubMed ID: 36005269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent extended-spectrum β-lactamase-positive Escherichia coli chronic prostatitis successfully treated with a combination of fosfomycin and doxycycline.
    Cunha BA; Gran A; Raza M
    Int J Antimicrob Agents; 2015 Apr; 45(4):427-9. PubMed ID: 25662814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant
    Zhanel GG; Zhanel MA; Karlowsky JA
    Can J Infect Dis Med Microbiol; 2018; 2018():1404813. PubMed ID: 29666664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fosfomycin for bacterial prostatitis: a review.
    Kwan ACF; Beahm NP
    Int J Antimicrob Agents; 2020 Oct; 56(4):106106. PubMed ID: 32721595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic prostatitis caused by extended-spectrum β-lactamase-producing
    Almeida F; Santos Silva A; Silva Pinto A; Sarmento A
    IDCases; 2019; 15():e00493. PubMed ID: 30766796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
    Raja NS
    J Infect Public Health; 2019; 12(6):843-846. PubMed ID: 31176606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefoxitin-based antibiotic therapy for extended-spectrum β-lactamase-producing Enterobacteriaceae prostatitis: a prospective pilot study.
    Demonchy E; Courjon J; Ughetto E; Durand M; Risso K; Garraffo R; Roger PM
    Int J Antimicrob Agents; 2018 Jun; 51(6):836-841. PubMed ID: 29378342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral fosfomycin for the treatment of chronic bacterial prostatitis.
    Karaiskos I; Galani L; Sakka V; Gkoufa A; Sopilidis O; Chalikopoulos D; Alivizatos G; Giamarellou E
    J Antimicrob Chemother; 2019 May; 74(5):1430-1437. PubMed ID: 30796442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of fosfomycin for multidrug-resistant gram-negative infections.
    Bassetti M; Graziano E; Berruti M; Giacobbe DR
    Curr Opin Infect Dis; 2019 Dec; 32(6):617-625. PubMed ID: 31567411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fosfomycin trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis: Results of a pilot study.
    Cai T; Tamanini I; Mattevi D; Verze P; Palmieri A; Malossini G; Mirone V; Novelli A; Tascini C; Johansen TEB
    Int J Antimicrob Agents; 2020 Jul; 56(1):105935. PubMed ID: 32156620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fosfomycin Susceptibility in Multidrug-Resistant Enterobacteriaceae Species and Vancomycin-Resistant Enterococci Urinary Isolates.
    Ou LB; Nadeau L
    Can J Hosp Pharm; 2017; 70(5):368-374. PubMed ID: 29109580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS; Loeb M; Leto D; Brooks AA
    Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged course of Fosfomycin-Trometamol for chronic prostatitis: an unknown good option.
    Denes E
    Scand J Urol; 2021 Aug; 55(4):344-345. PubMed ID: 34060413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidisciplinary approach to prostatitis.
    Magri V; Boltri M; Cai T; Colombo R; Cuzzocrea S; De Visschere P; Giuberti R; Granatieri CM; Latino MA; Larganà G; Leli C; Maierna G; Marchese V; Massa E; Matteelli A; Montanari E; Morgia G; Naber KG; Papadouli V; Perletti G; Rekleiti N; Russo GI; Sensini A; Stamatiou K; Trinchieri A; Wagenlehner FME
    Arch Ital Urol Androl; 2019 Jan; 90(4):227-248. PubMed ID: 30655633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Oral Fosfomycin-Trometamol in Male Urinary Tract Infections with Multidrug-Resistant Enterobacterales.
    Bouiller K; Zayet S; Lalloz PE; Potron A; Gendrin V; Chirouze C; Klopfenstein T
    Antibiotics (Basel); 2022 Feb; 11(2):. PubMed ID: 35203801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidrug-resistant Gram-negative infections: what are the treatment options?
    Giamarellou H; Poulakou G
    Drugs; 2009 Oct; 69(14):1879-901. PubMed ID: 19747006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fosfomycin, interesting alternative drug for treatment of urinary tract infections created by multiple drug resistant and extended spectrum β-lactamase producing strains.
    Yeganeh-Sefidan F; Ghotaslou R; Akhi MT; Sadeghi MR; Mohammadzadeh-Asl Y; Bannazadeh Baghi H
    Iran J Microbiol; 2016 Apr; 8(2):125-31. PubMed ID: 27307978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occurrence of multidrug resistance to oral antibiotics among Escherichia coli urine isolates from outpatient departments in Germany: extended-spectrum β-lactamases and the role of fosfomycin.
    Kresken M; Pfeifer Y; Hafner D; Wresch R; Körber-Irrgang B;
    Int J Antimicrob Agents; 2014 Oct; 44(4):295-300. PubMed ID: 25223936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.